Neither stenting nor endarterectomy provided a boost versus medical therapy alone in patients with asymptomatic stenosis.
A phase 2a trial of NMD Pharma’s rare disease prospect ignaseclant has missed its primary endpoint. | A phase 2a trial of NMD ...
Life runs on instructions you never see. Every cell reads DNA, turns that message into RNA, and then builds proteins that ...
This is the January 2026 edition of Anchovy News. Here you will find articles concerning ICANN, the domain name industry and ...
Macrolides are an important class of antibiotics that includes drugs such as azithromycin and erythromycin, which are widely used to treat a range of infections, including pneumonia and skin ...
News-Medical.Net on MSN
Olive oil type matters for cognition and gut health in older adults
By Tarun Sai Lomte A large cohort study suggests that not all olive oils are equal, with virgin olive oil showing favorable ...
Alphabet Inc. operates a diversified technology platform Search and advertising anchor core operations Global digital services span multiple industries Alphabet Inc. (NASDAQ:GOOG) remains a central ...
PSCI shared perspective on how artificial intelligence is influencing information technology roles across project-based and ...
The Luxury Chalet Company released an industry announcement addressing the expanding presence of artificial intelligence ...
Five days isolated in complete darkness retunes the senses. Scientist Kiana Aran explains how sensors help to share the ...
Thomson Reuters Corporation ( TRI:CA) Q4 2025 Earnings Call February 5, 2026 8:30 AM EST Good day, everyone, and welcome to ...
NMD Pharma is accelerating ignaseclant’s clinical development in CMT alongside multiple near-term clinical catalysts across its neuromuscular pipeline, with Phase 2 studies in spinal muscular atrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results